Touchlight awarded Best Emerging UK Biotech Company
We are delighted to announce that Touchlight has been awarded Best Emerging UK Biotech Company at the industry-leading OBN awards, reflecting the significant progress we have made in developing our innovative DNA synthesis platform.
- ENDS -
About Touchlight
Touchlight is a privately-owned biotechnology company based in London, U.K., focussed on the discovery and development of DNA-based genetic medicines, including DNA vaccines and gene therapies. Touchlight has developed a novel, synthetic DNA vector known as “doggybone DNA” or dbDNA™.
dbDNA™ is a minimal, linear, covalently closed structure, that eliminates bacterial sequences. Touchlight’s revolutionary enzymatic production platform enables unprecedented speed, scale, and the ability to target genes with a size and complexity that is impossible with current technologies.
Touchlight is applying dbDNA across advanced therapeutic modalities, both in-house and with partners. The company also provides contract manufacturing capabilities to produce dbDNA as a critical starting material for advanced therapy production through its manufacturing arm, Touchlight DNA Services.
Issued for and on behalf of Touchlight by Instinctif Partners.
For more information please contact:
Jonny Ohlson, CEO | Tim Watson |
Robin Bodicoat, Head of Marketing | Agnes Stephens |
E: info@touchlight.com | E: touchlight@instinctif.com |
T: +44 20 8481 9200 | T: +44 20 7457 2020 |